Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
500 participants
INTERVENTIONAL
2010-06-30
2017-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome
NCT01518192
Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans
NCT03584919
Duration of Antibiotic Treatment of Erythema Migrans
NCT00910715
Doxycycline in Therapy of Erythema Migrans
NCT01475708
Inflammatory Mediators in Erythema Migrans
NCT03956212
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MEM-ceftriaxone
ceftriaxone
intravenously, 2 g, qd, 15 days
MEM-doxycycline
doxycycline
orally, 100 mg, bid, 15 days
controls
No interventions assigned to this group
EM-doxycycline
erythema migrans patients treated with doxycycline
orally, 100 mg, bid, 15 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ceftriaxone
intravenously, 2 g, qd, 15 days
doxycycline
orally, 100 mg, bid, 15 days
erythema migrans patients treated with doxycycline
orally, 100 mg, bid, 15 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregnancy or lactation
* immunocompromised status
* serious adverse event to doxycycline or beta lactam antibiotic
* taking antibiotic with antiborrelial activity within 10 days
15 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Franc Strle
M.D., PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Franc Strle, MD
Role: STUDY_CHAIR
UMC Ljubljana
Dasa Stupica, MD
Role: PRINCIPAL_INVESTIGATOR
UMC Ljubljana, Department of Infectious Diseases Ljubljana, Slovenia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UMC Ljubljana, Department of Infectious Diseases
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Veluscek M, Bajrovic FF, Strle F, Stupica D. Doxycycline-induced photosensitivity in patients treated for erythema migrans. BMC Infect Dis. 2018 Aug 3;18(1):365. doi: 10.1186/s12879-018-3270-y.
Stupica D, Veluscek M, Blagus R, Bogovic P, Rojko T, Cerar T, Strle F. Oral doxycycline versus intravenous ceftriaxone for treatment of multiple erythema migrans: an open-label alternate-treatment observational trial. J Antimicrob Chemother. 2018 May 1;73(5):1352-1358. doi: 10.1093/jac/dkx534.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MEM-0510
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.